Conjunctivitis Market (By Type: Bacterial Conjunctivitis, Viral Conjunctivitis, and Allergic Conjunctivitis; By Patients Type: Pediatric and Adults; By Drug Class: Antibiotics, Anti-Histaminic, Decongestant, Steroid Drugs, and Others) - Global Market Size, Share, Growth, Trends Analysis, Regional Outlook and Forecasts 2023 - 2032

The global conjunctivitis market size was estimated at USD 4.80 billion in 2022 and is predicted to surpass around USD 8.08 billion by 2032, expanding immensive CAGR of 5.40% during the estimate period 2023 to 2032. 

Conjunctivitis Market Size 2023 To 2032

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Key Takeaways 

  • Conjunctivitis is expected to dominate the North American market.
  • The Allergic Conjunctivitis segment took the lead in market share in 2022
  • Market revenue is primarily driven by adult patient demographics.
  • Histamine blockers will lead the way in generating revenue in the conjunctivitis market.

Conjunctivitis Market Size in U.S. 2023 To 2032

The U.S. conjunctivitis market size accounted for USD 1.11 billion in 2022 and is projected to grow around USD 1.88 billion by 2032, at a CAGR of 5.40% from 2023 to 2032.

U.S. Conjunctivitis Market Size 2023 To 2032

North America is Estimated to be the Largest Market for Conjunctivitis

The detailed research report covers significant prospects and inclinations of conjunctivitis products throughout different regions including Europe, North America, Asia-Pacific, Africa, Middle East, and Latin America. By region, conjunctivitis market is led by North America due to early application of latest technologies and availability of latest technology infrastructure. Europe reported the second maximum share predominantly due to presence of key companies. Asia-Pacific is also anticipated to witness the rapid growth rate, on account of increasing healthcare expenditure.

Global Conjunctivitis Market 2021-2030

Major Trends in the Conjunctivitis Industry:

Patents on medication such as Lotemax, Patanol, Pataday, and Lastacaft are expected to expire during the forecast period, as well as other medications. Though the frequency of conjunctivitis is higher, the rate of treatment use is not, as the contamination usually rectifies on its own. Treatment is usually sought only when the condition persists or when the infection starts affecting the daily activities of an individual. As the infection is highly contagious, proper maintenance of hygienic conditions is necessary.

Conjunctivitis, also known as pink eye, is an infection in or irritation of the conjunctiva. It disturbs a person's eyes and might be the result of a virus, bacteria, or allergen. Allergens such as pollen, smoke, eye drops, dust mites, perfumes, and cosmetics can result in conjunctivitis. It is typically associated with soreness of the eye accompanied by the release of mucous releases. Although the ailment usually heals without medicine, antibiotics are usually used for treatment to avoid problems due to irritation of the eye.

The timely use of medication to treat the condition helps keep it under control. This can be ensured through educating people about the condition and conducting awareness campaigns. For instance, as part of the efforts of the Lebanese Ministry of Public Health and the Lebanese Ministry of Education and Higher Education, the University of Balamand's Faculty of Health Sciences conducted a conjunctivitis awareness campaign for the students, faculty, and staff of the university. Similarly, Planned Parenthood Arizona published a report about the connection between sexually transmitted infections and conjunctivitis. Educating the public on the treatment options for conjunctivitis increases the chances of individuals identifying the infection and treating it early with medication.

Treatment depends on the stage of conjunctivitis along with the experience of the optometrist. Experienced physicians understand the root cause of the condition easily, which helps reduce the patient's intake of unnecessary medication. Proper treatment reduces the incidence of the condition and avoids the chances of the condition worsening. The treatment options available for conjunctivitis are as follows

Crucial factors accountable for market growth are:

  • Increased exposure to chemicals and pollutants
  • Rising awareness of condition
  • Exploring specific treatment for viral conjunctivitis
  • Tentative approval of pipeline candidates

COVID-19 Impact on Global Conjunctivitis Market

Most of the leading nationswere forced into lockdown in order to control the coronavirus outbreak. That has led to disruption in the industry's supply chain. Because of this situation, most of the pharmaceutical companies globally are currently concentrating on saving their commerce and cash flow, instead of investing in manufacturing products.Key companies operating in the worldwide conjunctivitis industry are also facing issues to run their facilities and operate at full capacity to achieve their production target.

Report Scope of the Conjunctivitis Market

Report Highlights Details
Market Size USD 8.08 billion by 2032
Growth Rate CAGR of 5.40% From 2023 to 2032
Base Year 2022
Historic Data 2019 to 2021
Forecast Period 2023 to 2032
Segments Covered Patients, Drug Class, Patients Type
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)
Companies Mentioned Atopix Therapeutics Ltd., Allegran, Ocular Therapeutix, Inc., Santen Pharmaceutical Co. Ltd., Novartis, Boehringer Ingelheim, Pfizer Inc, Allegran, Sun Pharma, Sirion Therapeutics, Inc.


Significant Market Trends:

Allergic Conjunctivitis Segment Reported Foremost Market Stake in 2022

The allergic conjunctivitis displayed the major share in the worldwide conjunctivitis market in 2022. High prevalence of allergic conjunctivitis due to high exposure to allergen are the key reason for highest market stake of software segment. The factors such as strong product pipeline and high R&D expenditure are expected to retain the dominance of allergic conjunctivitis in the near future.

The bacterial conjunctivitis segment is anticipated grow at the maximum CAGR through the forecast time-frame mainly due to high prevalence.

Adults Patient Types Dominated the Market Revenue

Conjunctivitis is highly prevalent among the adult population. Augmented exposure to damaging pollutants and substances is resulting in growth in the quantity of conjunctivitis incidence worldwide. People employed in chemical plants and persons exposed to automobile fumes tend to get allergic conjunctivitis. The rising consciousness of the condition and its handling options are driving market growth.

Anti-Histaminic Will Dominate the Conjunctivitis Market Revenue By Drug Class

The prevalent use of anti-histaminic in the effective treatment of conjunctivitis is the key reason for high market share. Steroid Drugs will expand at highest CAGR during the forecast time-frame.

Top Players contending in the Market:

The companies focusing on research and development are expected to lead the global conjunctivitis market. Leading competitors contending in global conjunctivitis market are as follows:

  • Atopix Therapeutics Ltd.
  • Allegran
  • Ocular Therapeutix, Inc.
  • Santen Pharmaceutical Co. Ltd.
  • Novartis
  • Boehringer Ingelheim
  • Pfizer Inc
  • Allegran
  • Sun Pharma
  • Sirion Therapeutics, Inc.

In order to well recognize the present status of conjunctivitis, and policies implemented by the foremost nations, Precedence Research projected the future progress of the conjunctivitis market. This research report bids quantitative and qualitative insights on conjunctivitis market and valuation of market size and progress trend for probable market segments.

Major Market Segments Covered:

By Type

  • Bacterial Conjunctivitis
  • Viral Conjunctivitis
  • Allergic Conjunctivitis

By Patients Type

  • Pediatric
  • Adults

By Drug Class

  • Antibiotics
  • Anti-Histaminic
  • Decongestant
  • Steroid Drugs
  • Others

By Geography

  • North America
      • U.S.
      • Canada
  • Europe
      • Germany
      • France
      • United Kingdom
      • Rest of Europe
  • Asia Pacific
      • China
      • Japan
      • India
      • Southeast Asia
      • Rest of Asia Pacific
  • Latin America
      • Brazil
      • Rest of Latin America
  • Middle East & Africa (MEA)
      • GCC
      • North Africa
      • South Africa
      • Rest of Middle East & Africa

Frequently Asked Questions

What is the current size of the global conjunctivitis market?
According to Precedence Research, the global conjunctivitis market size was reached at USD 4.80 billion in 2022 and is projected to hit over USD 8.08 billion by 2032.
What is the CAGR of global conjunctivitis market?
The global conjunctivitis market is exhibiting at a CAGR of 5.40% during forecast period 2023 to 2032.
Which factors driving the conjunctivitis market growth?
Factors such as increasing prevalence of conjunctivitis, increasing healthcare expenditure, rising exposure to allergens, highly contagious nature of conjunctivitis are driving the growth of conjunctivitis market. Moreover, Additional features that are expected to fuel this business are integration of latest technologies and growing investment by major players.
How much is the revenue share of North America in the global conjunctivitis market?
the North America region dominated the worldwide market with a market share of higher than 43% In 2022,
Which region is anticipated to register fastest growth rate in the conjunctivitis market?
The Asia Pacific region is projected to grow at the highest CAGR of around 5.35% in the estimate period due to increasing healthcare expenditure.
Which segment accounted for the largest conjunctivitis market share?
Among the type segment, allergic conjunctivitis dominated the overall market in 2022. High prevalence of allergic conjunctivitis due to high exposure to allergen is the foremost factors attributing to its large market share.
Which key companies are functioning in the global conjunctivitis market?
The key companies functioning in the worldwide conjunctivitis market are Atopix Therapeutics Ltd., Allegran, Ocular Therapeutix, Inc., Santen Pharmaceutical Co. Ltd., Novartis, Boehringer Ingelheim, Pfizer Inc, Allegran, Sun Pharma, and Sirion Therapeutics, Inc. among others.
Why conjunctivitis?
Conjunctivitis is a contamination of the conjunctiva, a slim membrane layering the white portion of the sclera, eye, or the internal surface of the lids. Conjunctivitis can be very contagious and expand easily within large collections of people. Occasionally, especially in children, the ailment can affect visualization. In such situations, clinicians need to be knowledgeable immediately for effective and primary treatment.


   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500


No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Get a Sample